MedTrace Logo

STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy

NCT06337097 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 980

Last updated 2026-01-20

No results posted yet for this study

Summary

To learn if monitoring blood levels of heart injury (troponin levels) in cancer participants treated with immune checkpoint inhibitors will lead to decreased heart-related side effects.

Conditions

  • Immune Checkpoint Therapy

Interventions

DIAGNOSTIC_TEST

Troponin surveillance

Troponin will be monitored prior to each immune checkpoint inhibitor infusion for the first 12 weeks of therapy.

OTHER

Standard of care

Standard of care if symptoms arise then evaluation with cardiac biomarkers and/or further cardiac testing.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Nicolas Palaskas, MD · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-02
Primary Completion
2026-12-31
Completion
2028-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06337097 on ClinicalTrials.gov